In experimental mouse NASH, pharmacologic inhibition of CCR2 and 5 diminishes the recruitment of proinflammatory macrophages leading to amelioration of liver injury and inflammation (11). The gene discussed is CCR2; the disease is metabolic dysfunction-associated steatohepatitis.